Claims
- 1. A compound having analgesic activity of the general formula: ##STR112## including the purified stereoisomers and pharmaceutically acceptable salts thereof, wherein: ##STR113## R.sup.a1 is selected from the group consisting of hydroxy, halogen, C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl (wherein the substituent is C.sub.1-4 alkoxy, hydroxy or perhalo), C.sub.1-4 alkoxy, substituted C.sub.1-4 alkoxy (wherein the substituent is perfluoro), C.sub.1-4 alkylthio, cyano, nitro, amino, C.sub.1-4 alkylamino, diC.sub.1-4 alkylamino, C.sub.1-4 alkylsulfonyl, C.sub.1-4 alkylsulfinyl, phenyl, phenylthio, C.sub.1-4 acylamino, carboxy, C.sub.1-4 acyl and benzoyl;
- R.sup.a2 is selected from the group consisting of halogen or C.sub.1-4 alkyl;
- R.sup.b is 5-, 6-, or 7-position substituted and selected from the group consisting of hydrogen and C.sub.1-4 alkyl; and
- R.sup.c is selected from the group consisting of hydrogen, C.sub.1-4 alkyl, substituted C.sub.1-4 alkyl (wherein the substituent is one or two phenyl groups or diC.sub.1-4 alkylamino), C.sub.1-4 alkenyl, benzyl, C.sub.1-6 cycloalkylmethyl and C.sub.1-6 cycloalkyl;
- with the proviso that there is 0 or 1 unsaturated bond in the isoindole ring and with the proviso that where the stereoisomer is:
- a) the 3a.beta., 4.beta., 7a.alpha. diastereomer, then a double bond joins the 5- and 6-position carbons or the 6- and 7-position carbons;
- b) the 3a.beta., 4.alpha., 7a.alpha. or the 3a.beta., 4.alpha., 7a.beta. diastereomers, then the double bond joins the 5- and 6-position carbons; and
- c) the 3a.beta., 4.alpha., 7a.beta.diastereomer, then the double bond joins the 6- and 7-position carbons.
- 2. The compound of claim 1 of the general formula: ##STR114## including the purified stereoisomers thereof.
- 3. The compound of claim 1 of the general formula: ##STR115## including the purified stereoisomers thereof.
- 4. The compound of claim 1 of the general formula: ##STR116## including the purified stereoisomers thereof.
- 5. The compound of claim 1 of the general formula: ##STR117## including the purified stereoisomers thereof.
- 6. The compound of claim 1 of the general formula: ##STR118## including the purified stereoisomers thereof.
- 7. The compound of claim 1 of the general formula: ##STR119## including the purified stereoisomers thereof.
- 8. The compound of claim 1 wherein: ##STR120##
- 9. The compound of claim 1 wherein:
- R.sup.a1 is selected from the group consisting of hydroxy, bromine, chlorine, fluorine, methyl, ethyl, n-propyl, i-propyl, t-butyl, methoxymethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, trichloromethyl, methoxy, ethoxy, t-butoxy, trifluoromethoxy, methylthio, ethylthio, n-propylthio, cyano, nitro, amino, methylamino, ethylamino, n-propylamino, dimethylamino, diethylamino, methylethylamino, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, phenyl, phenylthio, formylamido, acetamido, propionylamido, carboxy, formyl, acetyl, propionyl and benzoyl.
- 10. The compound of claim 1 wherein:
- R.sup.a2 is selected from the group consisting of bromine, chlorine, fluorine, methyl, ethyl, n-propyl, i-propyl and t-butyl.
- 11. The compound of claim 1 wherein:
- R.sup.b is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl and t-butyl.
- 12. The compound of claim 1 wherein:
- R.sup.c are selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, t-butyl, benzyl, diphenylmethyl, dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminomethyl, diethylaminoethyl, allyl, benzyl, cyclopropylmethyl, cyclopropyl and cyclohexylmethyl.
- 13. The compound of claim 1 wherein said pharmaceutically acceptable salt is a salt made with an acid selected from the group consisting of hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, proprionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benezenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic and a salt made with sacchrine.
- 14. A compound selected from the group consisting of: ##STR121## wherein R.sup.a, R.sup.b and R.sup.c are simultaneously selected from the group consisting of:
- ______________________________________R.sup.a R.sup.b R.sup.c______________________________________4'-F 5-Me Me,3'-methoxy H Me,3'-methoxy H H,3'-CF.sub.3 H Me,3'-methoxy H benzyl,2',3'-dimethoxy H Me,3',4'-dichloro H Me,3'-OH H Me,-- H Me,4'-CF.sub.3 H Me,3'-CF.sub.3 H n-butyl,4'-NO.sub.2 H Me,4'-NH.sub.2 H Me,4'-NHCOCH.sub.3 H Me,4'-Cl H Me,2'-Cl H Me,2',5'-Cl H Me,4'-F H Me,4'-methoxy H Me,3',4'-dimethoxy H Me,4'-i-propyl H Me,4'-CN H Me,4'-Br H Me,4'-SMe H Me,4'-SO.sub.2 Me H Me, and3'-methoxy H benzyl,______________________________________
- including the purified stereoisomers thereof.
- 15. A compound selected from the group consisting of: ##STR122## including the purified stereoisomers thereof.
- 16. The compound of claim 15 selected from the group consisting of: ##STR123##
- 17. A pharmaceutical composition effective as an analgesic in mammals comprising a pharmaceutically acceptable carrier and an effective amount of the compound of claim 1.
- 18. A method for inducing an analgesic effect in mammals comprising the step of administering an effective amount of the compound of claim 1 in admixture with a pharmaceutically acceptable carrier.
RELATED APPLICATIONS
This is a Continuation-In-Part of Ser. No. 99,965, filed Jul. 29, 1993 which is a Continuation-In-Part of Ser. No. 38,571, filed Mar. 26, 1993 both are now abandoned.
US Referenced Citations (3)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0514273A1 |
May 1992 |
EPX |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
99965 |
Jul 1993 |
|
Parent |
38571 |
Mar 1993 |
|